Prabitha Prabhakaran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Prabitha Prabhakaran has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Bannimath Gurupadayya
JSS Academy of Higher Education & Research
5 shared publications - Erica Alves
Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research
5 shared publications - Aishwarya Bharathi H. M.
Department of Pharmaceutical Chemistry, JSS College of Pharmacy JSS Academy of Higher Education & Research Mysuru Karnataka India
4 shared publications - Chikkappaiahnayaka Santhosh
Department of Studies in Chemistry University of Mysore Mysuru Karnataka India
3 shared publications - Dipen Purohit
Analytical Development & Quality Control, Navinta LLC, Ewing, USA
3 shared publications - Maralinganadoddi Panchegowda Sadashiva
Department of Studies in Chemistry University of Mysore Mysuru Karnataka India
3 shared publications
Latest Publications
- 8 September 2026
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- p. 1-17
Rational Design and In Silico Evaluation of a Dual-Action Antimicrobial Peptide Targeting Efflux Pump and Membrane Integrity in Pseudomonas aeruginosa
The increasing prevalence of multidrug-resistant (MDR) Pseudomonas aeruginosa, largely associated with overexpression of the MexAB–OprM efflux pump, highlights the need for alternative antimicrobial strategies. In this study, antimicrobial peptide (AMP) candidates were rationally designed using the Artificial Neural Network (ANN) and Random Forest (RF) models implemented in the CAMPR4 platform. Approximately 18,000 AMP sequences were screened, resulting in nine candidate peptides that were subsequently evaluated for physicochemical properties, predicted hemolytic activity, and antimicrobial potential using the dbAMP framework. Five non-hemolytic peptides (1ANN, 2ANN, 4RF, 5RF, and 6RF) were selected for further analysis based on their predicted physicochemical characteristics and antimicrobial profiles. Molecular docking against the three components of the MexAB–OprM efflux pump (MexA, MexB, and OprM) predicted binding affinities ranging from − 7.1 to − 14.1 kcal mol⁻¹. Among the evaluated peptides, 2ANN was the only peptide predicted to form a hydrogen bond between Lys15 and Asp61 of MexA. Molecular dynamics simulations demonstrated that the 2ANN–MexA complex remained structurally stable over 200 ns, while membrane simulations showed spontaneous adsorption of 2ANN onto a Gram-negative membrane and persistent membrane association throughout the simulation. Collectively, these computational analyses identified 2ANN as a promising AMP candidate for further investigation against MDR P. aeruginosa. However, as the findings are based exclusively on computational prediction and simulation, experimental validation, including peptide synthesis, antimicrobial susceptibility testing, hemolytic assays, and efflux pump inhibition studies, is required to confirm its biological activity and mechanism of action.
- 8 September 2026
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- p. 1-17
Rational Design and In Silico Evaluation of a Dual-Action Antimicrobial Peptide Targeting Efflux Pump and Membrane Integrity in Pseudomonas aeruginosa
The increasing prevalence of multidrug-resistant (MDR) Pseudomonas aeruginosa, largely associated with overexpression of the MexAB–OprM efflux pump, highlights the need for alternative antimicrobial strategies. In this study, antimicrobial peptide (AMP) candidates were rationally designed using the Artificial Neural Network (ANN) and Random Forest (RF) models implemented in the CAMPR4 platform. Approximately 18,000 AMP sequences were screened, resulting in nine candidate peptides that were subsequently evaluated for physicochemical properties, predicted hemolytic activity, and antimicrobial potential using the dbAMP framework. Five non-hemolytic peptides (1ANN, 2ANN, 4RF, 5RF, and 6RF) were selected for further analysis based on their predicted physicochemical characteristics and antimicrobial profiles. Molecular docking against the three components of the MexAB–OprM efflux pump (MexA, MexB, and OprM) predicted binding affinities ranging from − 7.1 to − 14.1 kcal mol⁻¹. Among the evaluated peptides, 2ANN was the only peptide predicted to form a hydrogen bond between Lys15 and Asp61 of MexA. Molecular dynamics simulations demonstrated that the 2ANN–MexA complex remained structurally stable over 200 ns, while membrane simulations showed spontaneous adsorption of 2ANN onto a Gram-negative membrane and persistent membrane association throughout the simulation. Collectively, these computational analyses identified 2ANN as a promising AMP candidate for further investigation against MDR P. aeruginosa. However, as the findings are based exclusively on computational prediction and simulation, experimental validation, including peptide synthesis, antimicrobial susceptibility testing, hemolytic assays, and efflux pump inhibition studies, is required to confirm its biological activity and mechanism of action.
- 1 July 2026
- Published by Bentham Science Publishers Ltd. in Current Analytical Chemistry
- Vol. 22 (6) , 1012-1044
Advancements in Mass Spectrometry Imaging for Cancer Research: From Tumor Profiling to Personalized Medicine
Introduction: Mass Spectrometry Imaging (MSI) is a label-free analytical technique that enables spatially resolved molecular profiling of biomolecules in tissue sections. By simultaneously mapping proteins, lipids, and metabolites, MSI has significantly advanced cancer research by revealing tumor heterogeneity, metabolic reprogramming, and drug distribution patterns—key factors in precision oncology. Methods: This review is based on a comprehensive literature survey using databases such as Pub- Med, Scopus, and Web of Science. Studies were selected based on their relevance to recent innovations in MSI, particularly within cancer research and translational applications. Foundational landmark studies were also included to provide historical context and technological evolution. Results: Significant technological progress has been made in Matrix-Assisted Laser Desorption/ Ionization (MALDI) and Desorption Electrospray Ionization (DESI), including the development of MALDI-2 post-ionization and improvements in ambient DESI. These advancements have enhanced spatial resolution (to sub-10 μm), sensitivity, and molecular coverage. MSI applications have enabled high-resolution mapping of tumor microenvironments, drug localization, and discovery of spatially defined biomarkers. Additionally, integrative MSI approaches support multi-omic profiling, which aids in cancer subtype classification and provides insights into drug resistance and metabolic vulnerabilities. Discussion: MALDI and DESI offer complementary advantages. MALDI excels in proteomic and biomarker studies with high spatial fidelity, while DESI operates under ambient conditions and is ideal for lipidomics and in situ drug mapping. The integration of MSI with other spatial omics platforms and data-driven techniques has enhanced its utility in understanding tumor biology and therapeutic outcomes. Conclusion: MSI is poised to become a cornerstone of precision oncology and spatial biology. While challenges remain in standardization, data complexity, and clinical adoption, continued advances in instrumentation, ambient ionization, and artificial intelligence–assisted data analysis are accelerating its translational impact. Ongoing innovations promise to bridge the gap between experimental cancer research and routine clinical applications.
- 1 July 2026
- Published by Bentham Science Publishers Ltd. in Current Analytical Chemistry
- Vol. 22 (6) , 1012-1044
Advancements in Mass Spectrometry Imaging for Cancer Research: From Tumor Profiling to Personalized Medicine
Introduction: Mass Spectrometry Imaging (MSI) is a label-free analytical technique that enables spatially resolved molecular profiling of biomolecules in tissue sections. By simultaneously mapping proteins, lipids, and metabolites, MSI has significantly advanced cancer research by revealing tumor heterogeneity, metabolic reprogramming, and drug distribution patterns—key factors in precision oncology. Methods: This review is based on a comprehensive literature survey using databases such as Pub- Med, Scopus, and Web of Science. Studies were selected based on their relevance to recent innovations in MSI, particularly within cancer research and translational applications. Foundational landmark studies were also included to provide historical context and technological evolution. Results: Significant technological progress has been made in Matrix-Assisted Laser Desorption/ Ionization (MALDI) and Desorption Electrospray Ionization (DESI), including the development of MALDI-2 post-ionization and improvements in ambient DESI. These advancements have enhanced spatial resolution (to sub-10 μm), sensitivity, and molecular coverage. MSI applications have enabled high-resolution mapping of tumor microenvironments, drug localization, and discovery of spatially defined biomarkers. Additionally, integrative MSI approaches support multi-omic profiling, which aids in cancer subtype classification and provides insights into drug resistance and metabolic vulnerabilities. Discussion: MALDI and DESI offer complementary advantages. MALDI excels in proteomic and biomarker studies with high spatial fidelity, while DESI operates under ambient conditions and is ideal for lipidomics and in situ drug mapping. The integration of MSI with other spatial omics platforms and data-driven techniques has enhanced its utility in understanding tumor biology and therapeutic outcomes. Conclusion: MSI is poised to become a cornerstone of precision oncology and spatial biology. While challenges remain in standardization, data complexity, and clinical adoption, continued advances in instrumentation, ambient ionization, and artificial intelligence–assisted data analysis are accelerating its translational impact. Ongoing innovations promise to bridge the gap between experimental cancer research and routine clinical applications.
- 29 May 2026
- Published by Taylor & Francis in Bioanalysis
- p. 1-12
Quantification of oxaliplatin and lansoprazole in tumor tissue homogenates by LC–MS/MS: a fit-for-purpose bioanalytical approach
1. Breast cancer remains the most prevalent malignancy among women worldwide, with epidemiological estimates for 2020 indicating over two million new cases and approximately seven lakh associated d...
- 29 May 2026
- Published by Taylor & Francis in Bioanalysis
- p. 1-12
Quantification of oxaliplatin and lansoprazole in tumor tissue homogenates by LC–MS/MS: a fit-for-purpose bioanalytical approach
1. Breast cancer remains the most prevalent malignancy among women worldwide, with epidemiological estimates for 2020 indicating over two million new cases and approximately seven lakh associated d...
- Open Access
- 14 April 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (15) , e06670
Iodine‐Promoted Synthesis of 3,5‐Disubstituted 1,2,4‐Thiadiazoles From Thiooxamates and Their Acetylcholinesterase Inhibitory Activity
A practical and transition‐metal‐free protocol has been developed for the synthesis of 3,5‐disubstituted 1,2,4‐thiadiazoles via iodine‐promoted oxidative dimerization of alkyl/arylmethyl thiooxamates. This transformation proceeds rapidly under mild conditions through sequential oxidative S─N and N─C bond formation. The method exhibits broad substrate scope and excellent functional group tolerance, affording the desired thiadiazoles in good yields. The structure of one of the products was confirmed by single‐crystal x‐ray diffraction. Furthermore, the synthesized compounds were evaluated for in vitro acetylcholinesterase inhibitory (AChEI) activity, with compound 3d exhibiting promising activity compared to the standard drug rivastigmine.
- 14 April 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (15) , e06670
Open AccessIodine‐Promoted Synthesis of 3,5‐Disubstituted 1,2,4‐Thiadiazoles From Thiooxamates and Their Acetylcholinesterase Inhibitory Activity
A practical and transition‐metal‐free protocol has been developed for the synthesis of 3,5‐disubstituted 1,2,4‐thiadiazoles via iodine‐promoted oxidative dimerization of alkyl/arylmethyl thiooxamates. This transformation proceeds rapidly under mild conditions through sequential oxidative S─N and N─C bond formation. The method exhibits broad substrate scope and excellent functional group tolerance, affording the desired thiadiazoles in good yields. The structure of one of the products was confirmed by single‐crystal x‐ray diffraction. Furthermore, the synthesized compounds were evaluated for in vitro acetylcholinesterase inhibitory (AChEI) activity, with compound 3d exhibiting promising activity compared to the standard drug rivastigmine.
- 15 March 2026
- Published by Taylor & Francis in Critical Reviews in Analytical Chemistry
- p. 1-42
Smart Enantioseparation: A Critical Review of Instrumentation, Automation, and Data-Driven Strategies in Analytical Chirality
Analytical chirality occupies a transitional phase in modern analytical science. While advances in column chemistry, detector sensitivity, and instrumental precision have substantially improved ena...
- 15 March 2026
- Published by Taylor & Francis in Critical Reviews in Analytical Chemistry
- p. 1-42
Smart Enantioseparation: A Critical Review of Instrumentation, Automation, and Data-Driven Strategies in Analytical Chirality
Analytical chirality occupies a transitional phase in modern analytical science. While advances in column chemistry, detector sensitivity, and instrumental precision have substantially improved ena...
- 8 January 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (1) , e01670
An Expedient Synthesis of 2‐Acylthiazoles and 2‐Acyl‐4‐methyl‐5‐acetylthiazoles Using α‐Ketothioamides as Potential Acetylcholinesterase Inhibitors
Herein, report a simple and efficient strategy for the synthesis of 1,3 thiazole from the easily accessible α‐ketothioamides. The thioamide synthetic equivalents react smoothly with bromoacetals and 3‐chloropentane‐2,4‐dione to afford a series of substituted thiazoles 4a – l and 6a – l , demonstrating a high degree of thioamide functionalization. The reported procedure stands up due to the rapid reaction time with metal‐free mild conditions rendering it an attractive option for thiazole synthesis. The resulting compounds were evaluated for their neuroprotective effects through in vitro acetylcholinesterase (AChE) inhibitory activity. Among the synthesized molecules, compound 6j exhibited the most significant inhibitory effect, surpassing the standard drug rivastigmine in activity.
- 8 January 2026
- Published by Wiley in Chemistry & Biodiversity
- Vol. 23 (1) , e01670
An Expedient Synthesis of 2‐Acylthiazoles and 2‐Acyl‐4‐methyl‐5‐acetylthiazoles Using α‐Ketothioamides as Potential Acetylcholinesterase Inhibitors
Herein, report a simple and efficient strategy for the synthesis of 1,3 thiazole from the easily accessible α‐ketothioamides. The thioamide synthetic equivalents react smoothly with bromoacetals and 3‐chloropentane‐2,4‐dione to afford a series of substituted thiazoles 4a – l and 6a – l , demonstrating a high degree of thioamide functionalization. The reported procedure stands up due to the rapid reaction time with metal‐free mild conditions rendering it an attractive option for thiazole synthesis. The resulting compounds were evaluated for their neuroprotective effects through in vitro acetylcholinesterase (AChE) inhibitory activity. Among the synthesized molecules, compound 6j exhibited the most significant inhibitory effect, surpassing the standard drug rivastigmine in activity.
- Open Access
- 6 January 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
IN SILICO INVESTIGATION OF CONVOLVULUS PROSTRATUS AS A POTENTIAL SOURCE OF Α-GLUCOSIDASE INHIBITORS FOR DIABETIC MANAGEMENT
Objective: Diabetes mellitus (DM) remains a major global health concern, and inhibition of intestinal α-glucosidase is a well-established therapeutic approach for managing postprandial hyperglycemia. Convolvulus prostrates (C. prostratus) contains several phytochemicals with reported antidiabetic relevance. This study aimed to computationally assess selected constituents from C. prostratus for their potential α-glucosidase interactions using an integrated in silico strategy. Methods: Molecular docking, molecular mechanics–generalized born surface area binding free energy calculations, 100 ns molecular dynamics (MD) simulations, and absorption, distribution, metabolism, excretion, and toxicity predictions were performed to evaluate the interaction profiles and drug-likeness of prioritized phytoconstituents against human maltase–glucoamylase (PDB ID: 3TOP). Results: Among the screened compounds, A18 (identified as quercetin, a well-known flavonoid previously reported in C. prostratus), showed comparatively favorable docking affinity (ΔG = −9.549 kcal/mol) and MM-GBSA binding energy (ΔG_bind = −31.44 kcal/mol) relative to the other constituents evaluated. MD simulations indicated that the quercetin–enzyme complex maintained stable binding, with consistent interactions involving key catalytic residues such as Asp1157, Asp1279, and Asp1526. ADMET profiling suggested good oral absorption and acceptable physicochemical characteristics, while noting that its predicted blood–brain barrier permeability may represent a potential liability for an intestinal enzyme inhibitor. Conclusion: This study provides computational support for quercetin’s contributory role as one of the phytochemicals in C. prostratus capable of interacting with α-glucosidase. While quercetin demonstrated favorable in silico interaction and pharmacokinetic features compared with the other evaluated constituents, these findings primarily reinforce its known bioactivity and highlight the need for further in vitro and in vivo validation to substantiate its therapeutic relevance.
- 6 January 2026
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Applied Pharmaceutics
Open AccessIN SILICO INVESTIGATION OF CONVOLVULUS PROSTRATUS AS A POTENTIAL SOURCE OF Α-GLUCOSIDASE INHIBITORS FOR DIABETIC MANAGEMENT
Objective: Diabetes mellitus (DM) remains a major global health concern, and inhibition of intestinal α-glucosidase is a well-established therapeutic approach for managing postprandial hyperglycemia. Convolvulus prostrates (C. prostratus) contains several phytochemicals with reported antidiabetic relevance. This study aimed to computationally assess selected constituents from C. prostratus for their potential α-glucosidase interactions using an integrated in silico strategy. Methods: Molecular docking, molecular mechanics–generalized born surface area binding free energy calculations, 100 ns molecular dynamics (MD) simulations, and absorption, distribution, metabolism, excretion, and toxicity predictions were performed to evaluate the interaction profiles and drug-likeness of prioritized phytoconstituents against human maltase–glucoamylase (PDB ID: 3TOP). Results: Among the screened compounds, A18 (identified as quercetin, a well-known flavonoid previously reported in C. prostratus), showed comparatively favorable docking affinity (ΔG = −9.549 kcal/mol) and MM-GBSA binding energy (ΔG_bind = −31.44 kcal/mol) relative to the other constituents evaluated. MD simulations indicated that the quercetin–enzyme complex maintained stable binding, with consistent interactions involving key catalytic residues such as Asp1157, Asp1279, and Asp1526. ADMET profiling suggested good oral absorption and acceptable physicochemical characteristics, while noting that its predicted blood–brain barrier permeability may represent a potential liability for an intestinal enzyme inhibitor. Conclusion: This study provides computational support for quercetin’s contributory role as one of the phytochemicals in C. prostratus capable of interacting with α-glucosidase. While quercetin demonstrated favorable in silico interaction and pharmacokinetic features compared with the other evaluated constituents, these findings primarily reinforce its known bioactivity and highlight the need for further in vitro and in vivo validation to substantiate its therapeutic relevance.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Chemistry
- Vol. 2026 (1) , 2211953
Computational Exploration of Biphenyl Derivatives as PD‐L1 Inhibitors for TNBC Using Docking, Molecular Dynamics, MM‐GBSA, DFT, and AI/ML‐Based QSAR Modeling
Triple negative breast cancer (TNBC) remains a leading cause of cancer‐related mortality among women, creating an urgent need for new therapeutic strategies. This study aims to design potential PD‐L1 inhibitors using an in silico approach, integrating molecular docking with quantitative structure–activity relationship (QSAR) modeling in the discovery of promising candidates for immunotherapy in TNBC. Around 12 compounds were selected based on binding affinity equal to or greater than 9.5 kcal/mol. Binding analysis was done to select a lead compound. The reference ligand exhibited a binding affinity of −7.1 kcal/mol at the PD‐1/PD‐L1 interface, whereas the selected compound 3 with improved binding affinity (−13.4 kcal/mol) showed key interactions with critical residues Tyr56, Met115, Ala121, and Asp122, suggesting a comparatively stronger predicted binding affinity toward the PD‐L1 interface relative to the reference compound, within the limitations of docking‐based evaluation. The compound 3‐7DY7 complex demonstrated enhanced stability during 100 ns molecular dynamics (MD) simulations, maintaining low RMSD and strong hydrogen–bond interactions, supported by a favorable MM‐GBSA binding free energy (−118.994 kcal/mol). Compound 3 exhibited a slightly higher HOMO energy (−0.184 eV) compared to reference (−0.219 eV), indicating a greater ability to donate electrons. Consequently, compound 3 also showed a higher nucleophilicity index ( N = 8.935 eV), suggesting that it is more susceptible to electrophilic attack. Based on the QSAR analysis, the calculated pIC 50 value of compound 3 was 8.8. The QSAR modeling ( R 2 = 0.974, RMSE = 0.244, MAE = 0.167) confirmed robust predictive capacity. These results highlight compound 3 as a promising inhibitor of PDL‐1. This candidate could be prioritized for subsequent chemical synthesis and in vitro bioassays to confirm the computational findings.
- 1 January 2026
- Published by Wiley in Journal of Chemistry
- Vol. 2026 (1) , 2211953
Open AccessComputational Exploration of Biphenyl Derivatives as PD‐L1 Inhibitors for TNBC Using Docking, Molecular Dynamics, MM‐GBSA, DFT, and AI/ML‐Based QSAR Modeling
Triple negative breast cancer (TNBC) remains a leading cause of cancer‐related mortality among women, creating an urgent need for new therapeutic strategies. This study aims to design potential PD‐L1 inhibitors using an in silico approach, integrating molecular docking with quantitative structure–activity relationship (QSAR) modeling in the discovery of promising candidates for immunotherapy in TNBC. Around 12 compounds were selected based on binding affinity equal to or greater than 9.5 kcal/mol. Binding analysis was done to select a lead compound. The reference ligand exhibited a binding affinity of −7.1 kcal/mol at the PD‐1/PD‐L1 interface, whereas the selected compound 3 with improved binding affinity (−13.4 kcal/mol) showed key interactions with critical residues Tyr56, Met115, Ala121, and Asp122, suggesting a comparatively stronger predicted binding affinity toward the PD‐L1 interface relative to the reference compound, within the limitations of docking‐based evaluation. The compound 3‐7DY7 complex demonstrated enhanced stability during 100 ns molecular dynamics (MD) simulations, maintaining low RMSD and strong hydrogen–bond interactions, supported by a favorable MM‐GBSA binding free energy (−118.994 kcal/mol). Compound 3 exhibited a slightly higher HOMO energy (−0.184 eV) compared to reference (−0.219 eV), indicating a greater ability to donate electrons. Consequently, compound 3 also showed a higher nucleophilicity index ( N = 8.935 eV), suggesting that it is more susceptible to electrophilic attack. Based on the QSAR analysis, the calculated pIC 50 value of compound 3 was 8.8. The QSAR modeling ( R 2 = 0.974, RMSE = 0.244, MAE = 0.167) confirmed robust predictive capacity. These results highlight compound 3 as a promising inhibitor of PDL‐1. This candidate could be prioritized for subsequent chemical synthesis and in vitro bioassays to confirm the computational findings.
- Open Access
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
Pharmacophore-driven design and biological evaluation of heterocyclic PDE4B inhibitors for Alzheimer's disease
Alzheimer's disease (AD) is a complex neurodegenerative condition marked by a gradual loss of cognitive function, impaired synaptic signalling, and sustained neuroinflammatory responses.
- 1 January 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
Open AccessPharmacophore-driven design and biological evaluation of heterocyclic PDE4B inhibitors for Alzheimer's disease
Alzheimer's disease (AD) is a complex neurodegenerative condition marked by a gradual loss of cognitive function, impaired synaptic signalling, and sustained neuroinflammatory responses.